Literature DB >> 26141060

PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma.

Yiwei Wang1, Hang Wang, Qi Zhao, Yu Xia, Xiaoyi Hu, Jianming Guo.   

Abstract

The incidence of kidney cancer has been increasing globally during the past two decades. Renal cell carcinoma (RCC) is the most aggressive subtype of kidney cancer, which usually deteriorates with epithelial-mesenchymal transition (EMT) that facilitates the migration and invasion of cancer cells. Till now, the underlying mechanism remains unclear. In this study, we demonstrated that programmed death ligand 1 (PD-L1/B7-H1/CD274) could induce EMT and enhance RCC cell cancer stemness through up-regulation of SREBP-1c. Furthermore, we found that PD-L1 is up-regulated in human RCC metastases. These results, taken together, provide evidence for a novel mechanism of PD-L1 in RCC progression, suggesting that there is a close relationship between EMT and immune escape signaling pathways in RCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26141060     DOI: 10.1007/s12032-015-0655-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Authors:  Wanqing Iris Zhi; Jenny J Kim
Journal:  Ann Cancer Res       Date:  2014

2.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation.

Authors:  Evelien Rysman; Koen Brusselmans; Katryn Scheys; Leen Timmermans; Rita Derua; Sebastian Munck; Paul P Van Veldhoven; David Waltregny; Veerle W Daniëls; Jelle Machiels; Frank Vanderhoydonc; Karine Smans; Etienne Waelkens; Guido Verhoeven; Johannes V Swinnen
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.

Authors:  Qiqun Zeng; Weidong Li; Di Lu; Zhenzhen Wu; Hongxia Duan; Yongting Luo; Jing Feng; Dongling Yang; Li Fu; Xiyun Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-30       Impact factor: 11.205

4.  Report of cancer incidence and mortality in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou
Journal:  Ann Transl Med       Date:  2014-07

5.  B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin.

Authors:  Yujia Cao; Lu Zhang; Yosuke Kamimura; Patcharee Ritprajak; Masaaki Hashiguchi; Sachiko Hirose; Miyuki Azuma
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

7.  B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Authors:  Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

Review 8.  [OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells].

Authors:  S P Medvedev; A I Shevchenko; N A Mazurok; S M Zakiian
Journal:  Genetika       Date:  2008-12

9.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

10.  The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.

Authors:  Heevy Al-Chaqmaqchi; Behnam Sadeghi; Manuchehr Abedi-Valugerdi; Sulaiman Al-Hashmi; Mona Fares; Raoul Kuiper; Joachim Lundahl; Moustapha Hassan; Ali Moshfegh
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more
  35 in total

1.  Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.

Authors:  Bo Zhang; Wei Yu; Xueru Feng; Zheng Zhao; Yu Fan; Yisen Meng; Shuai Hu; Yun Cui; Qun He; Hong Zhang; Dong Li; Zhisong He; Liqun Zhou; Jie Jin; Wenke Han
Journal:  Med Oncol       Date:  2017-04-13       Impact factor: 3.064

2.  Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.

Authors:  Shaojia Wang; Jiajia Li; Jie Xie; Fei Liu; Yachen Duan; Yong Wu; Shenglin Huang; Xianghuo He; Ziliang Wang; Xiaohua Wu
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

3.  Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.

Authors:  Arezoo Rasti; Zahra Madjd; Maryam Abolhasani; Mitra Mehrazma; Leila Janani; Leili Saeednejad Zanjani; Mojgan Asgari
Journal:  Clin Exp Med       Date:  2017-12-04       Impact factor: 3.984

4.  Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Authors:  Fumi Kawakami; Kanishka Sircar; Jaime Rodriguez-Canales; Bryan M Fellman; Diana L Urbauer; Pheroze Tamboli; Nizar M Tannir; Eric Jonasch; Ignacio I Wistuba; Christopher G Wood; Jose A Karam
Journal:  Cancer       Date:  2017-08-22       Impact factor: 6.860

Review 5.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

6.  Lipid Metabolism and Immune Checkpoints.

Authors:  Qianjin Liao; Yujuan Zhou; Longzheng Xia; Deliang Cao
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

8.  STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Authors:  Elisabet Cuyàs; Almudena Pérez-Sánchez; Vicente Micol; Javier A Menendez; Joaquim Bosch-Barrera
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 9.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

10.  Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells.

Authors:  Lin Zha; Qiang Cao; Xin Cui; Fenfen Li; Houjie Liang; Bingzhong Xue; Hang Shi
Journal:  Med Oncol       Date:  2016-01-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.